MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL)
Open Access
- 9 November 2019
- journal article
- letter
- Published by Wiley in HemaSphere
- Vol. 3 (6), e305
- https://doi.org/10.1097/hs9.0000000000000305
Abstract
An abstract is unavailable. This article is available as a PDF only.This publication has 15 references indexed in Scilit:
- Double-hit DLBCL: should we limit FISH testing?Blood, 2018
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphologyBlood, 2018
- Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesNature Medicine, 2018
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysisBritish Journal of Haematology, 2015
- Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysisBlood, 2014
- Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOPLaboratory Investigation, 2014
- Double hit lymphoma: the MD Anderson Cancer Center clinical experienceBritish Journal of Haematology, 2014
- Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program StudyHaematologica, 2012
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survivalBlood, 2009